Scorr-Insert
X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Prasterone

            Therapeutic Area: Neurology

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Millicent Pharma Limited

            Deal Size: $125.0 million Upfront Cash: $20.0 million

            Deal Type: Divestment May 21, 2020

            Details:

            Transaction allows AMAG to advance its strategic focus on Feraheme, Makena and its pipeline, consistent with previously announced plans.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Apomorphine Hydrochloride

            Therapeutic Area: Neurology

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 21, 2020

            Details:

            In a Phase 3 study, patients with Parkinson’s disease treated with KYNMOBI experienced significant improvements in motor symptoms at 30 minutes, compared to placebo.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Diclofenac Potassium

            Therapeutic Area: Neurology

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Assertio Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Merger May 20, 2020

            Details:

            The merger creates a growing commercial pharmaceutical company with neurology, inflammation and pain products.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Phytocannabinoid

            Therapeutic Area: Neurology

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Cannaworx

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition May 19, 2020

            Details:

            Cannaworx and its Principals twelve products for market launch in the coming year, including two novel products derived from the company's pain relief phytocannabinoid formulations. Acquisition of 5 leaf labs offers access to more than 50 sales members in 21 states.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Onasemnogene abeparvovec

            Therapeutic Area: Neurology

            Highest Development Status: Approved Product Type: Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 19, 2020

            Details:

            Zolgensma has demonstrated significant and clinically meaningful therapeutic benefit in pre-symptomatic and symptomatic SMA, including prolonged event-free survival and achievement of motor milestones, sustained for 5 years post-dosing.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Rimegepant

            Therapeutic Area: Neurology

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 18, 2020

            Details:

            Data spotlights NURTEC as the first and only CGRP-targeting agent using a quick-dissolve ODT technology for fast onset of action, return to normal function within one hour and sustained efficacy for 48 hours after a single dose.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Apomorphine Hydrochloride

            Therapeutic Area: Neurology

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Supernus Pharmaceuticals

            Deal Size: $530.0 million Upfront Cash: $300.0 million

            Deal Type: Acquisition April 28, 2020

            Details:

            Acquisition adds three products developed and sold in the U.S. market with a late-stage development candidate in the Supernus pipeline: APOKYN ®, MYOBLOC ® XADAGO ® and Apomorphine Infusion Pump.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Rimegepant

            Therapeutic Area: Neurology

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Genpharm Services

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement April 27, 2020

            Details:

            Biohaven and Genpharm's agreement will bring NURTEC™ ODT, the first oral, quick-dissolve, calcitonin gene related peptide antagonist to patients in the Middle East and the Gulf Region.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Meloxicam

            Therapeutic Area: Neurology

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 23, 2020

            Details:

            Two virtual posters highlight new ANJESO clinical results, along with health resource utilization data, when administered preoperatively following Total Knee Arthroplasty.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Rimegepant

            Therapeutic Area: Neurology

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Medison Pharma

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement April 16, 2020

            Details:

            Biohaven and Medison Pharma's partnership will bring NURTEC ODT, the first oral, quick-dissolve, calcitonin gene related peptide (CGRP) antagonist to patients in Israel.

            PharmaCompass